VIVUS Inc. (VVUS)

4.21
NASDAQ : Health Technology
Prev Close 4.33
Day Low/High 4.20 / 4.35
52 Wk Low/High 2.15 / 5.78
Avg Volume 106.40K
Exchange NASDAQ
Shares Outstanding 10.64M
Market Cap 46.08M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
FDA Loosens Restrictions on Vivus Weight-Loss Pill

FDA Loosens Restrictions on Vivus Weight-Loss Pill

Vivus' Qsymia will now be available at retail pharmacies.

Large Vivus Shareholder Seeks More Change

Large Vivus Shareholder Seeks More Change

A favorable FDA ruling on Qsymia's distribution is not enough for First Manhattan.

Arena Bulls, Bears Endure Annoyingly Long Wait for Belviq Launch

Arena Bulls, Bears Endure Annoyingly Long Wait for Belviq Launch

The DEA is taking its sweet time determining the abuse potential for Arena's weight-loss pill.

Vivus Piles New Debt On Top Of Excuses (Updated)

Vivus Piles New Debt On Top Of Excuses (Updated)

The $110 million loan suggests Vivus is still having trouble selling its weight loss pill.

Vivus (VVUS): Drugs' Featured Champion Of The Day

Vivus (VVUS): Drugs' Featured Champion Of The Day

Vivus was a winner within the drugs industry, rising 13 cents (1.2%) to $10.94 on light volume.

Vivus (VVUS): Today's Featured Drugs Laggard

Vivus (VVUS): Today's Featured Drugs Laggard

Vivus was a leading decliner within the drugs industry, falling 27 cents (-2.3%) to $11.27 on light volume.

Vivus (VVUS): Today's Featured Health Care Winner

Vivus (VVUS): Today's Featured Health Care Winner

Vivus was a winner within the health care sector, rising 32 cents (2.9%) to $11.42 on average volume.

The Five Dumbest Things on Wall Street This Week: March 1

The Five Dumbest Things on Wall Street This Week: March 1

Martha Stewart, Live Nation and Vivus - among others - make this week's list of the biggest business bloopers.

The 5 Dumbest Things on Wall Street: March 1

The 5 Dumbest Things on Wall Street: March 1

Here is this week's roundup of the dumbest actions on Wall Street.

Why Expect More Price Swings From These 4 Biotechs

Why Expect More Price Swings From These 4 Biotechs

Crish Lau, Kapitall Contributor  Companies in the biotechnology space are often trade like speculative investments. Speculation for FDA approvals may [...]

Vivus (VVUS): Today's Featured Health Care Laggard

Vivus (VVUS): Today's Featured Health Care Laggard

Vivus was a leading decliner within the health care sector, falling $1.52 (-12.3%) to $10.89 on heavy volume.

Dow Sings on Upbeat Data, Bernanke

Dow Sings on Upbeat Data, Bernanke

Major U.S. stock averages rebound from the prior session's swoon.

Vivus, Arena Drugs Fail to Burn Americans' Prodigious Fat

Vivus, Arena Drugs Fail to Burn Americans' Prodigious Fat

The companies face problems with their respective weight-loss drug launches.

Stock Futures Signal a Rebound; Macy's, Home Depot Rise

Stock Futures Signal a Rebound; Macy's, Home Depot Rise

Major U.S. stock averages are pointing to a higher open on Wall Street Tuesday after sharp declines the prior session.

5 Stocks Set to Soar on Bullish Earnings

5 Stocks Set to Soar on Bullish Earnings

These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.

Analysts' Actions: COF QCOM DECK HOT ESRX

Analysts' Actions: COF QCOM DECK HOT ESRX

Here are today's top research calls.

Wall Street Investors Aren't Eager to Own Arena Pharma Quite Yet

Wall Street Investors Aren't Eager to Own Arena Pharma Quite Yet

Institutional investor ownership flat in fourth quarter as Arena gears up to launch its weight loss pill.

EnteroMedics Weight-Loss Device Is A Pulsing Placebo

EnteroMedics Weight-Loss Device Is A Pulsing Placebo

The VBLOC device fails to help obese patients lose weight in a phase III study.

EnteroMedics: Fat Zapper or Pulsing Placebo?

EnteroMedics: Fat Zapper or Pulsing Placebo?

Soon-to-be released data will tell investors if EnteroMedics can be a player in the blockbuster obesity market.

Vivus (VVUS): Today's Featured Drugs Laggard

Vivus (VVUS): Today's Featured Drugs Laggard

Vivus was a leading decliner within the drugs industry, falling 59 cents (-4.5%) to $12.39 on average volume.

Weighing Possibility of Europe Rejecting Arena Pharma's Obesity Pill

Weighing Possibility of Europe Rejecting Arena Pharma's Obesity Pill

The consensus view of Europe approving Belviq could be overly optimistic.

TheStreet Quant Rating: D (Sell)